

# **ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and Genitourinary Cancers**

**PROGRAMME**

**ESMO  
ADVANCED COURSE**

**ZURICH SWITZERLAND  
25-26 NOVEMBER 2024**

**Co-Chairs**

Solange Peters, Switzerland  
Thomas Powles, United Kingdom

# ESMO ADVANCED COURSE PROGRAMME ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: THORACIC AND GENITOURINARY CANCERS

Zurich, Switzerland  
25-26 November 2024

**CO-CHAIRS** Solange Peters, Switzerland  
Thomas Powles, United Kingdom

**SPEAKERS** Lukas Bubendorf, Switzerland  
Anne-Marie Dingemans, The Netherlands  
Enriqueta Felip, Spain  
Antoine Italiano, France  
Yohann Loriot, France  
Alexander Meisel, Switzerland  
Albrecht Stenzinger, Germany  
Michiel van der Heijden, The Netherlands  
Gunhild von Amsberg, Germany

## LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



Supported by a grant from Pfizer Inc.

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Monday, 25 November 2024

---

- 09:00-09:10 **Welcome and introduction**
- 10' Welcome and learning objectives introduction  
*Solange Peters, CH and Thomas Powles, UK*
- 09:10-10:00 **Session 1 – Current landscape**  
**Chair: Thomas Powles, UK**
- 15' ADC clinical landscape in lung cancer  
*Solange Peters, CH*
- 15' ADC clinical landscape in GU cancers  
*Thomas Powles, UK*
- 20' Discussion
- 10:00-10:50 **Session 2 – ADC development and pharmacodynamics – Part I**  
**Chair: Thomas Powles, UK**
- 15' Mechanisms of action and resistance: ADC internalization, cleavage and mechanisms of resistance  
*Gunhild von Amsberg, DE*
- 15' ADC development: What are the considerations in early phase trials  
*Antoine Italiano, FR*
- 20' Discussion
- 10:50-11:20 Coffee break**
- 11:20-12:00 **Session 3 – Target assessment and rationale for combinations**  
**Chair: Thomas Powles, UK**
- 20' Considerations from pathology: Biomarker selection, on-target, off-tumour expression, off-target toxicities  
*Lukas Bubendorf, CH*
- 20' Discussion
- 12:00-12:35 **Session 4 – Next generation ADCs – Part I**  
**Chair: Solange Peters, CH**
- 20' How to develop rational combinations and sequencing  
*Michiel van der Heijden, NL*
- 15' Discussion
- 12:35-13:35 **Session 4 – Next generation ADCs – Part II**  
**Chair: Solange Peters, CH**
- 20' Developments in ADC constructs including bispecific ADCs  
*Albrecht Stenzinger, DE*
- 20' Additional innovative strategies: Cytokine conjugates, peptide-based conjugates  
*Albrecht Stenzinger, DE*
- 20' Discussion
- 13:35-14:30 Lunch**

- 14:30-15:20 **Session 5 – Developments across diseases**  
*Chair: Solange Peters, CH*
- 15' Future perspectives for lung cancer  
*Enriqueta Felip, ES*
- 15' Future perspectives for GU cancers  
*Alexander Meisel, CH*
- 20' Panel discussion: What can we learn from each other?  
*Anne-Marie Dingemans, NL, Enriqueta Felip, ES, Antoine Italiano, FR, Alexander Meisel, CH, Solange Peters, CH, Thomas Powles, UK*
- 15:20-15:50 **Coffee break**
- 19:30 **Networking dinner**

## Tuesday, 26 November 2024

---

- 08:35-09:00 **Session 2 – ADC development and pharmacodynamics – Part II**
- 15' Toxicity: Prediction, identification and treatment  
*Anne-Marie Dingemans, NL*
- 10' Discussion
- 09:00-12:30 **Workshop sessions**
- Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)
- 15' Introduction based on clinical cases presented by speakers
  - 40' Discussion
  - 5' Break
- Workshop 1** ADC trials in GU (bladder cancer)  
*Yohann Lorient, FR and Michiel van der Heijden, NL*
- Workshop 2** ADC trials in thoracic cancers  
*Lukas Bubendorf, CH and Enriqueta Felip, ES*
- Workshop 3** ADC related toxicities  
*Anne-Marie Dingemans, NL and Antoine Italiano, FR*
- 11:00-11:30 **Coffee break**
- 11:30-12:30 **Workshops continuation**
- 12:30-13:00 **Feedback on the workshops from each group**
- 13:00-13:15 **Synthesis and wrap-up**  
*Solange Peters, CH and Thomas Powles, UK*
- 13:15-14:15 **Lunch**